Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (394 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.829, 5-year impact factor: 4.312
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33744945763&partnerID=40&md5=51dc9a8b5692da3293ca33a4a3ae0912
Keywords: Bone Pain, Combined Therapy, Sr-89, Zoledronic Acid, Bisphosphonic Acid Derivative, Strontium 89, Adult, Aged, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Clinical Article, Clinical Feature, Controlled Study, Female, Human, Infection, Nephrotoxicity, Pain Assessment, Patient Monitoring, Physician, Rating Scale, Statistical Significance, Visual Analog Scale, 80 And Over, Bone Neoplasms, Breast Neoplasms, Combined Modality Therapy, Diphosphonates, Follow-Up Studies, Imidazoles, Middle Aged, Neoplasm Metastasis, Palliative Care, Prostatic Neoplasms, Strontium Radioisotopes, Time Factors, Treatment Outcome,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II of Naples, Italy
Department of Oncology, University Federico II of Naples, Italy
IRCCS, Neuromed, Pozzilli, Italy
Diagnostic Imaging, University of Naples Parthenope, Italy
References:
Reddi, A.H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: challenges and opportunities (2003) J. Bone Miner. Res., 18, pp. 190-19
Nielsen, O.S., Munro, A.J., Tannock, I.F., Bone metastases: pathophysiology and management policy (1991) J. Clin. Oncol., 9, pp. 509-524
Coleman, R.E., Rubens, R.D., The clinical course of bone metastases in breast cancer (1987) Br. J. Cancer, 55, pp. 61-66
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J. Cell Biol., 91, pp. 718-729
Ribiero, M., Ruff, P., Falkson, G., Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer (1997) Am. J. Clin. Oncol., 20, pp. 605-608
Posadas, E.M., Dahut, W.L., Gulley, J., The emerging role of bisphosphonates in prostate cancer (2004) Am. J. Ther., 11, pp. 60-73
Soloway, M.S., Ishikawa, S., van der Waag, R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL), pp. 53-56
Choong, P.F., The molecular basis of skeletal metastases (2003) Clin. Orthop., (415 SUPPL), pp. S19-S31
Behrens, J., Frixen, U., Schipper, J., Weidner, M., Birchmeier, W., Cell adhesion in invasion and metastasis (1992) Semin. Cell Biol., 3, pp. 169-178
Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells (1991) Cell, 65, pp. 13-24
Raisz, L.G., Physiology and pathophysiology of bone remodeling (1999) Clin. Chem., 45, pp. 1353-1358
Body, J.J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr. Opin. Oncol., 4, pp. 624-631
Hortobagyi, G.N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin. Oncol., 29 (3 SUPPL), pp. 134-144
Marcus, C.S., Saeed, S., Mlikotic, A., Mishkin, F., Pham, H.L., Javellana, T., Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP (2002) Clin. Nucl. Med., 27, pp. 427-430
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J. Nucl. Med., 46 (1 SUPPL), pp. 38S-47S
Mertens, W.C., Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy (1993) Semin. Oncol., 20 (3 SUPPL), pp. 49-55
Auclerc, G., Antoine, E.C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., Khayat, D., Management of advanced prostate cancer (2000) Oncologist, 5, pp. 36-44
Karnofsky, D.A., Meaningful clinical classification of therapeutic responses to anticancer drugs (1961) Clin. Pharmacol. Ther., 2, pp. 709-712
Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Palliation of bone pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J. Clin. Oncol., 16, pp. 1574-1581
Collins, C., Eary, J.F., Donaldson, G., Vernon, C., Bush, N.E., Petersdorf, S., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial (1993) J. Nucl. Med., 34, pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C.R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) J. Nucl. Med., 45, pp. 1358-1365
Tong, D., Gillick, L., Hendrickson, F.R., The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group (1982) Cancer, 50, pp. 893-899
Salazar, O.M., Rubin, P., Hendrickson, F.R., Komaki, R., Poulter, C., Newall, J., Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report (1986) Cancer, 58 (1), pp. 29-36
Mincey, B.A., Perez, E.A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clin. Proc., 79, pp. 810-816
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin. J. Oncol. Nurs., 7, pp. 641-646
Tannock, I., Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? (1985) J. Clin. Oncol., 3, pp. 1013-1021
Chisholm, G.D., Rana, A., Howard, G.C.W., Management options for painful carcinoma of the prostate (1993) Semin. Oncol., 20, pp. 34-37
Lipton, A., Theriault, R.L., Hortobagyi, G.N., Simeone, J., Knight, R.D., Mellars, K., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow up of two randomized, placebo-controlled trials (2000) Cancer, 88, pp. 1082-1090
Rosen, L.S., Gordon, D.H., Dugan Jr., W., Major, P., Eisenberg, P.D., Provencher, L., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion (2004) Cancer, 1, pp. 36-43
Sciuto, R., Festa, A., Pasqualoni, R., Semprebene, A., Rea, S., Bergomi, S., Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients (2001) Breast Cancer Res. Treat., 66, pp. 101-109
Rogers, M.J., New insights into the molecular mechanisms of action of bisphosphonates (2003) Curr. Pharm. Des., 9, pp. 2643-2658
van Beek, E.R., Cohen, L.H., Leroy, I.M., Ebetino, F.H., Lowik, C.W., Papapoulos, S.E., Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates (2003) Bone, 33, pp. 805-811
Reinholz, G.G., Getz, B., Pederson, L., Sanders, E.S., Subramaniam, M., Ingle, J.N., Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts (2000) Cancer Res., 60, pp. 6001-6007
Giuliani, N., Pedrazzoni, M., Negri, G., Passeri, G., Impicciatore, M., Girasole, G., Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo (1998) Bone, 22, pp. 455-461
Clezardin, P., Ebetino, F.H., Fournier, P.G., Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity (2005) Cancer Res., 65, pp. 4971-4974
Coleman, R.E., Bisphosphonates in breast cancer (2005) Ann. Oncol., 16, pp. 687-695
Bukowski, J.F., Dascher, C.C., Das, H., Alternative bisphosphonate targets and mechanisms of action (2005) Biochem. Biophys. Res. Commun., 328, pp. 746-750
Corso, A., Ferretti, E., Lunghi, M., Zappasodi, P., Mangiacavalli, S., De Amici, M., Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect (2005) Cancer, 104, pp. 118-125
Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Cordiali Fei, P., Di Cosimo, S., Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients (2005) Oncologia, 69, pp. 35-43
Chaplet, M., Detry, C., Deroanne, C., Fisher, L.W., Castronovo, V., Bellahcéne, A., Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition (2004) Biochem. J., 384, pp. 591-598
Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (2001) Cancer, 91, pp. 1191-1200
Lo Russo, P., Analysis of skeletal-related events in breast cancer and response to therapy (2001) Semin. Oncol., 28 (4 SUPPL), pp. 22-27
Powles, T.S., Paterson, S., Kanis, J.A., McCloskey, E., Ashley, S., Tidy, A., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer (2002) J. Clin. Oncol., 20, pp. 3219-3224
Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial (1999) J. Clin. Oncol., 17, pp. 846-854
Wang, R.F., Zhang, C.L., Zhu, S.L., Zhu, M., A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer (2003) Med. Princ. Pract., 12, pp. 97-101
Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases (1996) N. Eng. J. Med., 335, pp. 1785-1791
Wellington, K., Goa, K.L., Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy (2003) Drugs, 63, pp. 417-437
Carey, P.O., Lippert, M.C., Treatment of painful prostatic bone metastases with oral etidronate disodium (1988) Urology, 32, pp. 403-407
Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma (2002) J. Natl. Cancer Inst., 94, pp. 1458-1468
Vogel, C.L., Yanagihara, R.H., Wood, A.J., Schnell, F.M., Henderson, C., Kaplan, B.H., Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy (2004) Oncologist, 9, pp. 687-695
Saad, F., Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone (2002) Clin. Prostate Cancer, 1, pp. 145-152
Li, E.C., Davis, L.E., Zoledronic acid: a new parenteral bisphosphonate (2003) Clin. Ther., 25, pp. 2669-2708
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D., Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials (2001) J. Clin. Oncol., 19, pp. 558-567
Serafini, A.N., Therapy of metastatic bone pain (2001) J. Nucl. Med., 42, pp. 895-906
Altman, G.B., Lee, C.A., Strontium-89 for treatment of painful bone metastases from prostate cancer (1996) Oncol. Nurs. Forum, 23, pp. 523-527
Uchiyama, M., Narita, H., Makino, M., Sekine, H., Mori, Y., Fukumitsu, N., Strontium-89 therapy and imaging with bremsstrahlung in bone metastases (1997) Clin. Nucl. Med., 22, pp. 605-609
Baziotis, N., Yakoumakis, E., Zissimopoulos, A., Gerinicola-Tripali, X., Malamitsi, J., Proukakis, C.H., Strontium-89 in the treatment of bone metastases from breast cancer (1998) Oncology, 55, pp. 377-381
Pons, F., Herranz, R., Garcia, A., Vidal-Sicart, S., Conill, C., Grau, J.J., Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer (1997) Eur. J. Nucl. Med., 24, pp. 1210-1214
Morris, M.J., Scher, H.I., Clinical approaches to osseous metastases in prostate cancer (2003) The Oncologist, 2, pp. 161-173
Blake, G.M., Zivanovic, M.A., McEwan, A.J., Ackery, D.M., Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate (1986) Eur. J. Nucl. Med., 12, pp. 447-454
Nightengale, B., Brune, M., Blizzard, S.P., Ashley-Johnson, M., Slan, S., Strontium chloride Sr-89 for treating pain from metastatic bone disease (1995) Am. J. Health-Syst. Pharm., 52, pp. 2189-2195
Porter, A.T., McEwan, A.J.B., Powe, J.E., Reid, R., McGowan, D.G., Lukka, H., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer (1993) Int. J. Radiat. Oncol., Biol., Phys., 25, pp. 805-813
Quilty, P.M., Kirk, D., Bolger, J.J., Dearnaley, D.P., Lewington, V.J., Mason, M.D., A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer (1994) Radiother. Oncol., 31, pp. 33-40
Sciuto, R., Maini, C.L., Tofani, A., Fiumara, C., Scelsa, M.G., Broccatelli, M., Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89 (1996) Nucl. Med. Commun., 17, pp. 799-804
Tu, S., Millikan, R.E., Mengistu, B., Delpassand, E.S., Amato, R.J., Pagliaro, L.C., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial (2001) Lancet, 357, pp. 336-341
Hamdy, N.A., Papapoulos, S.E., The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates (2001) Semin. Nucl. Med., 31, pp. 62-68
Soerdjbalie-Maikoe, V., Pelger, R.C., Lycklama a Nijeholt, G.A., Arndt, J.W., Zwinderman, A.H., Papapoulos, S.E., Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton (2002) Eur. J. Nucl. Med. Mol. Imaging, 29, pp. 494-498
Perry, C.M., Figgitt, D.P., Zoledronic acid: a review of its use in patients with advanced cancer (2004) Drugs, 64, pp. 1197-1211
Body, J.J., Clinical research update: zoledronate (1997) Cancer, 80 (8 SUPPL), pp. 1699-1701
Bonabello, A., Galmozzi, M.R., Canaparo, R., Serpe, L., Zara, G.P., Long-term analgesic effect of clodronate in rodents (2003) Bone, 33, pp. 567-574
Robinson, R.G., Preston, D.F., Schiefelbein, M., Baxter, K.G., Strontium 89 therapy for the palliation of pain due to osseous metastases (1995) JAMA, 274, pp. 420-424
Lewington, V.J., McEwan, A.J., Ackery, D.M., Bayly, R.J., Keeling, D.H., Macleod, P.M., A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone (1991) Eur. J. Cancer, 27, pp. 954-958
Ware Jr., J.E., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection (1992) Care, 30, pp. 473-483
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., The functional assessment of cancer therapy scale: development and validation of the general measure (1993) J. Clin. Oncol., 11, pp. 570-579
Hwang, S.S., Chang, V.T., Kasimis, B., Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) J. Pain Symptom Manage., 23, pp. 190-200
Mertens, W.C., Stitt, L., Porter, A.T., Strontium-89 therapy and relief of pain in patients with prostate carcinoma metastatic to bone: a dose response relationship? (1993) Am. J. Clin. Oncol., 16, pp. 238-242
Conte, P.F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group (1996) J. Clin. Oncol., 14, pp. 2552-2559
Reddi, A. H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: challenges and opportunities (2003) J. Bone Miner. Res., 18, pp. 190-19
Nielsen, O. S., Munro, A. J., Tannock, I. F., Bone metastases: pathophysiology and management policy (1991) J. Clin. Oncol., 9, pp. 509-524
Coleman, R. E., Rubens, R. D., The clinical course of bone metastases in breast cancer (1987) Br. J. Cancer, 55, pp. 61-66
Keller, E. T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J. Cell Biol., 91, pp. 718-729
Posadas, E. M., Dahut, W. L., Gulley, J., The emerging role of bisphosphonates in prostate cancer (2004) Am. J. Ther., 11, pp. 60-73
Soloway, M. S., Ishikawa, S., van der Waag, R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL), pp. 53-56
Choong, P. F., The molecular basis of skeletal metastases (2003) Clin. Orthop., (415 SUPPL), pp. S19-S31
Raisz, L. G., Physiology and pathophysiology of bone remodeling (1999) Clin. Chem., 45, pp. 1353-1358
Body, J. J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr. Opin. Oncol., 4, pp. 624-631
Hortobagyi, G. N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin. Oncol., 29 (3 SUPPL), pp. 134-144
Marcus, C. S., Saeed, S., Mlikotic, A., Mishkin, F., Pham, H. L., Javellana, T., Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP (2002) Clin. Nucl. Med., 27, pp. 427-430
Lewington, V. J., Bone-seeking radionuclides for therapy (2005) J. Nucl. Med., 46 (1 SUPPL), pp. 38S-47S
Mertens, W. C., Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy (1993) Semin. Oncol., 20 (3 SUPPL), pp. 49-55
Karnofsky, D. A., Meaningful clinical classification of therapeutic responses to anticancer drugs (1961) Clin. Pharmacol. Ther., 2, pp. 709-712
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., Palliation of bone pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J. Clin. Oncol., 16, pp. 1574-1581
Salazar, O. M., Rubin, P., Hendrickson, F. R., Komaki, R., Poulter, C., Newall, J., Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report (1986) Cancer, 58 (1), pp. 29-36
Mincey, B. A., Perez, E. A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clin. Proc., 79, pp. 810-816
Reich, C. D., Advances in the treatment of bone metastases (2003) Clin. J. Oncol. Nurs., 7, pp. 641-646
Chisholm, G. D., Rana, A., Howard, G. C. W., Management options for painful carcinoma of the prostate (1993) Semin. Oncol., 20, pp. 34-37
Rosen, L. S., Gordon, D. H., Dugan Jr., W., Major, P., Eisenberg, P. D., Provencher, L., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion (2004) Cancer, 1, pp. 36-43
Rogers, M. J., New insights into the molecular mechanisms of action of bisphosphonates (2003) Curr. Pharm. Des., 9, pp. 2643-2658
van Beek, E. R., Cohen, L. H., Leroy, I. M., Ebetino, F. H., Lowik, C. W., Papapoulos, S. E., Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates (2003) Bone, 33, pp. 805-811
Reinholz, G. G., Getz, B., Pederson, L., Sanders, E. S., Subramaniam, M., Ingle, J. N., Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts (2000) Cancer Res., 60, pp. 6001-6007
Coleman, R. E., Bisphosphonates in breast cancer (2005) Ann. Oncol., 16, pp. 687-695
Bukowski, J. F., Dascher, C. C., Das, H., Alternative bisphosphonate targets and mechanisms of action (2005) Biochem. Biophys. Res. Commun., 328, pp. 746-750
Berenson, J. R., Rosen, L. S., Howell, A., Porter, L., Coleman, R. E., Morley, W., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (2001) Cancer, 91, pp. 1191-1200
Powles, T. S., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer (2002) J. Clin. Oncol., 20, pp. 3219-3224
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Gluck, S., Stewart, J. F., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial (1999) J. Clin. Oncol., 17, pp. 846-854
Wang, R. F., Zhang, C. L., Zhu, S. L., Zhu, M., A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer (2003) Med. Princ. Pract., 12, pp. 97-101
Carey, P. O., Lippert, M. C., Treatment of painful prostatic bone metastases with oral etidronate disodium (1988) Urology, 32, pp. 403-407
Vogel, C. L., Yanagihara, R. H., Wood, A. J., Schnell, F. M., Henderson, C., Kaplan, B. H., Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy (2004) Oncologist, 9, pp. 687-695
Li, E. C., Davis, L. E., Zoledronic acid: a new parenteral bisphosphonate (2003) Clin. Ther., 25, pp. 2669-2708
Serafini, A. N., Therapy of metastatic bone pain (2001) J. Nucl. Med., 42, pp. 895-906
Altman, G. B., Lee, C. A., Strontium-89 for treatment of painful bone metastases from prostate cancer (1996) Oncol. Nurs. Forum, 23, pp. 523-527
Morris, M. J., Scher, H. I., Clinical approaches to osseous metastases in prostate cancer (2003) The Oncologist, 2, pp. 161-173
Blake, G. M., Zivanovic, M. A., McEwan, A. J., Ackery, D. M., Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate (1986) Eur. J. Nucl. Med., 12, pp. 447-454
Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer (1993) Int. J. Radiat. Oncol., Biol., Phys., 25, pp. 805-813
Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Mason, M. D., A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer (1994) Radiother. Oncol., 31, pp. 33-40
Hamdy, N. A., Papapoulos, S. E., The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates (2001) Semin. Nucl. Med., 31, pp. 62-68
Perry, C. M., Figgitt, D. P., Zoledronic acid: a review of its use in patients with advanced cancer (2004) Drugs, 64, pp. 1197-1211
Body, J. J., Clinical research update: zoledronate (1997) Cancer, 80 (8 SUPPL), pp. 1699-1701
Robinson, R. G., Preston, D. F., Schiefelbein, M., Baxter, K. G., Strontium 89 therapy for the palliation of pain due to osseous metastases (1995) JAMA, 274, pp. 420-424
Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone (1991) Eur. J. Cancer, 27, pp. 954-958
Ware Jr., J. E., Sherbourne, C. D., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection (1992) Care, 30, pp. 473-483
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., The functional assessment of cancer therapy scale: development and validation of the general measure (1993) J. Clin. Oncol., 11, pp. 570-579
Hwang, S. S., Chang, V. T., Kasimis, B., Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) J. Pain Symptom Manage., 23, pp. 190-200
Mertens, W. C., Stitt, L., Porter, A. T., Strontium-89 therapy and relief of pain in patients with prostate carcinoma metastatic to bone: a dose response relationship? (1993) Am. J. Clin. Oncol., 16, pp. 238-242
Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group (1996) J. Clin. Oncol., 14, pp. 2552-2559
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.829, 5-year impact factor: 4.312
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33744945763&partnerID=40&md5=51dc9a8b5692da3293ca33a4a3ae0912
Keywords: Bone Pain, Combined Therapy, Sr-89, Zoledronic Acid, Bisphosphonic Acid Derivative, Strontium 89, Adult, Aged, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Clinical Article, Clinical Feature, Controlled Study, Female, Human, Infection, Nephrotoxicity, Pain Assessment, Patient Monitoring, Physician, Rating Scale, Statistical Significance, Visual Analog Scale, 80 And Over, Bone Neoplasms, Breast Neoplasms, Combined Modality Therapy, Diphosphonates, Follow-Up Studies, Imidazoles, Middle Aged, Neoplasm Metastasis, Palliative Care, Prostatic Neoplasms, Strontium Radioisotopes, Time Factors, Treatment Outcome,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II of Naples, Italy
Department of Oncology, University Federico II of Naples, Italy
IRCCS, Neuromed, Pozzilli, Italy
Diagnostic Imaging, University of Naples Parthenope, Italy
References:
Reddi, A.H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: challenges and opportunities (2003) J. Bone Miner. Res., 18, pp. 190-19
Nielsen, O.S., Munro, A.J., Tannock, I.F., Bone metastases: pathophysiology and management policy (1991) J. Clin. Oncol., 9, pp. 509-524
Coleman, R.E., Rubens, R.D., The clinical course of bone metastases in breast cancer (1987) Br. J. Cancer, 55, pp. 61-66
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J. Cell Biol., 91, pp. 718-729
Ribiero, M., Ruff, P., Falkson, G., Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer (1997) Am. J. Clin. Oncol., 20, pp. 605-608
Posadas, E.M., Dahut, W.L., Gulley, J., The emerging role of bisphosphonates in prostate cancer (2004) Am. J. Ther., 11, pp. 60-73
Soloway, M.S., Ishikawa, S., van der Waag, R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL), pp. 53-56
Choong, P.F., The molecular basis of skeletal metastases (2003) Clin. Orthop., (415 SUPPL), pp. S19-S31
Behrens, J., Frixen, U., Schipper, J., Weidner, M., Birchmeier, W., Cell adhesion in invasion and metastasis (1992) Semin. Cell Biol., 3, pp. 169-178
Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells (1991) Cell, 65, pp. 13-24
Raisz, L.G., Physiology and pathophysiology of bone remodeling (1999) Clin. Chem., 45, pp. 1353-1358
Body, J.J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr. Opin. Oncol., 4, pp. 624-631
Hortobagyi, G.N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin. Oncol., 29 (3 SUPPL), pp. 134-144
Marcus, C.S., Saeed, S., Mlikotic, A., Mishkin, F., Pham, H.L., Javellana, T., Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP (2002) Clin. Nucl. Med., 27, pp. 427-430
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J. Nucl. Med., 46 (1 SUPPL), pp. 38S-47S
Mertens, W.C., Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy (1993) Semin. Oncol., 20 (3 SUPPL), pp. 49-55
Auclerc, G., Antoine, E.C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., Khayat, D., Management of advanced prostate cancer (2000) Oncologist, 5, pp. 36-44
Karnofsky, D.A., Meaningful clinical classification of therapeutic responses to anticancer drugs (1961) Clin. Pharmacol. Ther., 2, pp. 709-712
Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Palliation of bone pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J. Clin. Oncol., 16, pp. 1574-1581
Collins, C., Eary, J.F., Donaldson, G., Vernon, C., Bush, N.E., Petersdorf, S., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial (1993) J. Nucl. Med., 34, pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C.R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) J. Nucl. Med., 45, pp. 1358-1365
Tong, D., Gillick, L., Hendrickson, F.R., The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group (1982) Cancer, 50, pp. 893-899
Salazar, O.M., Rubin, P., Hendrickson, F.R., Komaki, R., Poulter, C., Newall, J., Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report (1986) Cancer, 58 (1), pp. 29-36
Mincey, B.A., Perez, E.A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clin. Proc., 79, pp. 810-816
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin. J. Oncol. Nurs., 7, pp. 641-646
Tannock, I., Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? (1985) J. Clin. Oncol., 3, pp. 1013-1021
Chisholm, G.D., Rana, A., Howard, G.C.W., Management options for painful carcinoma of the prostate (1993) Semin. Oncol., 20, pp. 34-37
Lipton, A., Theriault, R.L., Hortobagyi, G.N., Simeone, J., Knight, R.D., Mellars, K., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow up of two randomized, placebo-controlled trials (2000) Cancer, 88, pp. 1082-1090
Rosen, L.S., Gordon, D.H., Dugan Jr., W., Major, P., Eisenberg, P.D., Provencher, L., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion (2004) Cancer, 1, pp. 36-43
Sciuto, R., Festa, A., Pasqualoni, R., Semprebene, A., Rea, S., Bergomi, S., Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients (2001) Breast Cancer Res. Treat., 66, pp. 101-109
Rogers, M.J., New insights into the molecular mechanisms of action of bisphosphonates (2003) Curr. Pharm. Des., 9, pp. 2643-2658
van Beek, E.R., Cohen, L.H., Leroy, I.M., Ebetino, F.H., Lowik, C.W., Papapoulos, S.E., Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates (2003) Bone, 33, pp. 805-811
Reinholz, G.G., Getz, B., Pederson, L., Sanders, E.S., Subramaniam, M., Ingle, J.N., Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts (2000) Cancer Res., 60, pp. 6001-6007
Giuliani, N., Pedrazzoni, M., Negri, G., Passeri, G., Impicciatore, M., Girasole, G., Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo (1998) Bone, 22, pp. 455-461
Clezardin, P., Ebetino, F.H., Fournier, P.G., Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity (2005) Cancer Res., 65, pp. 4971-4974
Coleman, R.E., Bisphosphonates in breast cancer (2005) Ann. Oncol., 16, pp. 687-695
Bukowski, J.F., Dascher, C.C., Das, H., Alternative bisphosphonate targets and mechanisms of action (2005) Biochem. Biophys. Res. Commun., 328, pp. 746-750
Corso, A., Ferretti, E., Lunghi, M., Zappasodi, P., Mangiacavalli, S., De Amici, M., Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect (2005) Cancer, 104, pp. 118-125
Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Cordiali Fei, P., Di Cosimo, S., Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients (2005) Oncologia, 69, pp. 35-43
Chaplet, M., Detry, C., Deroanne, C., Fisher, L.W., Castronovo, V., Bellahcéne, A., Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition (2004) Biochem. J., 384, pp. 591-598
Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (2001) Cancer, 91, pp. 1191-1200
Lo Russo, P., Analysis of skeletal-related events in breast cancer and response to therapy (2001) Semin. Oncol., 28 (4 SUPPL), pp. 22-27
Powles, T.S., Paterson, S., Kanis, J.A., McCloskey, E., Ashley, S., Tidy, A., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer (2002) J. Clin. Oncol., 20, pp. 3219-3224
Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial (1999) J. Clin. Oncol., 17, pp. 846-854
Wang, R.F., Zhang, C.L., Zhu, S.L., Zhu, M., A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer (2003) Med. Princ. Pract., 12, pp. 97-101
Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases (1996) N. Eng. J. Med., 335, pp. 1785-1791
Wellington, K., Goa, K.L., Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy (2003) Drugs, 63, pp. 417-437
Carey, P.O., Lippert, M.C., Treatment of painful prostatic bone metastases with oral etidronate disodium (1988) Urology, 32, pp. 403-407
Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma (2002) J. Natl. Cancer Inst., 94, pp. 1458-1468
Vogel, C.L., Yanagihara, R.H., Wood, A.J., Schnell, F.M., Henderson, C., Kaplan, B.H., Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy (2004) Oncologist, 9, pp. 687-695
Saad, F., Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone (2002) Clin. Prostate Cancer, 1, pp. 145-152
Li, E.C., Davis, L.E., Zoledronic acid: a new parenteral bisphosphonate (2003) Clin. Ther., 25, pp. 2669-2708
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D., Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials (2001) J. Clin. Oncol., 19, pp. 558-567
Serafini, A.N., Therapy of metastatic bone pain (2001) J. Nucl. Med., 42, pp. 895-906
Altman, G.B., Lee, C.A., Strontium-89 for treatment of painful bone metastases from prostate cancer (1996) Oncol. Nurs. Forum, 23, pp. 523-527
Uchiyama, M., Narita, H., Makino, M., Sekine, H., Mori, Y., Fukumitsu, N., Strontium-89 therapy and imaging with bremsstrahlung in bone metastases (1997) Clin. Nucl. Med., 22, pp. 605-609
Baziotis, N., Yakoumakis, E., Zissimopoulos, A., Gerinicola-Tripali, X., Malamitsi, J., Proukakis, C.H., Strontium-89 in the treatment of bone metastases from breast cancer (1998) Oncology, 55, pp. 377-381
Pons, F., Herranz, R., Garcia, A., Vidal-Sicart, S., Conill, C., Grau, J.J., Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer (1997) Eur. J. Nucl. Med., 24, pp. 1210-1214
Morris, M.J., Scher, H.I., Clinical approaches to osseous metastases in prostate cancer (2003) The Oncologist, 2, pp. 161-173
Blake, G.M., Zivanovic, M.A., McEwan, A.J., Ackery, D.M., Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate (1986) Eur. J. Nucl. Med., 12, pp. 447-454
Nightengale, B., Brune, M., Blizzard, S.P., Ashley-Johnson, M., Slan, S., Strontium chloride Sr-89 for treating pain from metastatic bone disease (1995) Am. J. Health-Syst. Pharm., 52, pp. 2189-2195
Porter, A.T., McEwan, A.J.B., Powe, J.E., Reid, R., McGowan, D.G., Lukka, H., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer (1993) Int. J. Radiat. Oncol., Biol., Phys., 25, pp. 805-813
Quilty, P.M., Kirk, D., Bolger, J.J., Dearnaley, D.P., Lewington, V.J., Mason, M.D., A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer (1994) Radiother. Oncol., 31, pp. 33-40
Sciuto, R., Maini, C.L., Tofani, A., Fiumara, C., Scelsa, M.G., Broccatelli, M., Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89 (1996) Nucl. Med. Commun., 17, pp. 799-804
Tu, S., Millikan, R.E., Mengistu, B., Delpassand, E.S., Amato, R.J., Pagliaro, L.C., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial (2001) Lancet, 357, pp. 336-341
Hamdy, N.A., Papapoulos, S.E., The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates (2001) Semin. Nucl. Med., 31, pp. 62-68
Soerdjbalie-Maikoe, V., Pelger, R.C., Lycklama a Nijeholt, G.A., Arndt, J.W., Zwinderman, A.H., Papapoulos, S.E., Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton (2002) Eur. J. Nucl. Med. Mol. Imaging, 29, pp. 494-498
Perry, C.M., Figgitt, D.P., Zoledronic acid: a review of its use in patients with advanced cancer (2004) Drugs, 64, pp. 1197-1211
Body, J.J., Clinical research update: zoledronate (1997) Cancer, 80 (8 SUPPL), pp. 1699-1701
Bonabello, A., Galmozzi, M.R., Canaparo, R., Serpe, L., Zara, G.P., Long-term analgesic effect of clodronate in rodents (2003) Bone, 33, pp. 567-574
Robinson, R.G., Preston, D.F., Schiefelbein, M., Baxter, K.G., Strontium 89 therapy for the palliation of pain due to osseous metastases (1995) JAMA, 274, pp. 420-424
Lewington, V.J., McEwan, A.J., Ackery, D.M., Bayly, R.J., Keeling, D.H., Macleod, P.M., A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone (1991) Eur. J. Cancer, 27, pp. 954-958
Ware Jr., J.E., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection (1992) Care, 30, pp. 473-483
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., The functional assessment of cancer therapy scale: development and validation of the general measure (1993) J. Clin. Oncol., 11, pp. 570-579
Hwang, S.S., Chang, V.T., Kasimis, B., Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) J. Pain Symptom Manage., 23, pp. 190-200
Mertens, W.C., Stitt, L., Porter, A.T., Strontium-89 therapy and relief of pain in patients with prostate carcinoma metastatic to bone: a dose response relationship? (1993) Am. J. Clin. Oncol., 16, pp. 238-242
Conte, P.F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group (1996) J. Clin. Oncol., 14, pp. 2552-2559
Reddi, A. H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: challenges and opportunities (2003) J. Bone Miner. Res., 18, pp. 190-19
Nielsen, O. S., Munro, A. J., Tannock, I. F., Bone metastases: pathophysiology and management policy (1991) J. Clin. Oncol., 9, pp. 509-524
Coleman, R. E., Rubens, R. D., The clinical course of bone metastases in breast cancer (1987) Br. J. Cancer, 55, pp. 61-66
Keller, E. T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J. Cell Biol., 91, pp. 718-729
Posadas, E. M., Dahut, W. L., Gulley, J., The emerging role of bisphosphonates in prostate cancer (2004) Am. J. Ther., 11, pp. 60-73
Soloway, M. S., Ishikawa, S., van der Waag, R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL), pp. 53-56
Choong, P. F., The molecular basis of skeletal metastases (2003) Clin. Orthop., (415 SUPPL), pp. S19-S31
Raisz, L. G., Physiology and pathophysiology of bone remodeling (1999) Clin. Chem., 45, pp. 1353-1358
Body, J. J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr. Opin. Oncol., 4, pp. 624-631
Hortobagyi, G. N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin. Oncol., 29 (3 SUPPL), pp. 134-144
Marcus, C. S., Saeed, S., Mlikotic, A., Mishkin, F., Pham, H. L., Javellana, T., Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP (2002) Clin. Nucl. Med., 27, pp. 427-430
Lewington, V. J., Bone-seeking radionuclides for therapy (2005) J. Nucl. Med., 46 (1 SUPPL), pp. 38S-47S
Mertens, W. C., Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy (1993) Semin. Oncol., 20 (3 SUPPL), pp. 49-55
Karnofsky, D. A., Meaningful clinical classification of therapeutic responses to anticancer drugs (1961) Clin. Pharmacol. Ther., 2, pp. 709-712
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., Palliation of bone pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J. Clin. Oncol., 16, pp. 1574-1581
Salazar, O. M., Rubin, P., Hendrickson, F. R., Komaki, R., Poulter, C., Newall, J., Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report (1986) Cancer, 58 (1), pp. 29-36
Mincey, B. A., Perez, E. A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clin. Proc., 79, pp. 810-816
Reich, C. D., Advances in the treatment of bone metastases (2003) Clin. J. Oncol. Nurs., 7, pp. 641-646
Chisholm, G. D., Rana, A., Howard, G. C. W., Management options for painful carcinoma of the prostate (1993) Semin. Oncol., 20, pp. 34-37
Rosen, L. S., Gordon, D. H., Dugan Jr., W., Major, P., Eisenberg, P. D., Provencher, L., Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion (2004) Cancer, 1, pp. 36-43
Rogers, M. J., New insights into the molecular mechanisms of action of bisphosphonates (2003) Curr. Pharm. Des., 9, pp. 2643-2658
van Beek, E. R., Cohen, L. H., Leroy, I. M., Ebetino, F. H., Lowik, C. W., Papapoulos, S. E., Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates (2003) Bone, 33, pp. 805-811
Reinholz, G. G., Getz, B., Pederson, L., Sanders, E. S., Subramaniam, M., Ingle, J. N., Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts (2000) Cancer Res., 60, pp. 6001-6007
Coleman, R. E., Bisphosphonates in breast cancer (2005) Ann. Oncol., 16, pp. 687-695
Bukowski, J. F., Dascher, C. C., Das, H., Alternative bisphosphonate targets and mechanisms of action (2005) Biochem. Biophys. Res. Commun., 328, pp. 746-750
Berenson, J. R., Rosen, L. S., Howell, A., Porter, L., Coleman, R. E., Morley, W., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (2001) Cancer, 91, pp. 1191-1200
Powles, T. S., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer (2002) J. Clin. Oncol., 20, pp. 3219-3224
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Gluck, S., Stewart, J. F., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial (1999) J. Clin. Oncol., 17, pp. 846-854
Wang, R. F., Zhang, C. L., Zhu, S. L., Zhu, M., A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer (2003) Med. Princ. Pract., 12, pp. 97-101
Carey, P. O., Lippert, M. C., Treatment of painful prostatic bone metastases with oral etidronate disodium (1988) Urology, 32, pp. 403-407
Vogel, C. L., Yanagihara, R. H., Wood, A. J., Schnell, F. M., Henderson, C., Kaplan, B. H., Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy (2004) Oncologist, 9, pp. 687-695
Li, E. C., Davis, L. E., Zoledronic acid: a new parenteral bisphosphonate (2003) Clin. Ther., 25, pp. 2669-2708
Serafini, A. N., Therapy of metastatic bone pain (2001) J. Nucl. Med., 42, pp. 895-906
Altman, G. B., Lee, C. A., Strontium-89 for treatment of painful bone metastases from prostate cancer (1996) Oncol. Nurs. Forum, 23, pp. 523-527
Morris, M. J., Scher, H. I., Clinical approaches to osseous metastases in prostate cancer (2003) The Oncologist, 2, pp. 161-173
Blake, G. M., Zivanovic, M. A., McEwan, A. J., Ackery, D. M., Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate (1986) Eur. J. Nucl. Med., 12, pp. 447-454
Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer (1993) Int. J. Radiat. Oncol., Biol., Phys., 25, pp. 805-813
Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Mason, M. D., A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer (1994) Radiother. Oncol., 31, pp. 33-40
Hamdy, N. A., Papapoulos, S. E., The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates (2001) Semin. Nucl. Med., 31, pp. 62-68
Perry, C. M., Figgitt, D. P., Zoledronic acid: a review of its use in patients with advanced cancer (2004) Drugs, 64, pp. 1197-1211
Body, J. J., Clinical research update: zoledronate (1997) Cancer, 80 (8 SUPPL), pp. 1699-1701
Robinson, R. G., Preston, D. F., Schiefelbein, M., Baxter, K. G., Strontium 89 therapy for the palliation of pain due to osseous metastases (1995) JAMA, 274, pp. 420-424
Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone (1991) Eur. J. Cancer, 27, pp. 954-958
Ware Jr., J. E., Sherbourne, C. D., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection (1992) Care, 30, pp. 473-483
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., The functional assessment of cancer therapy scale: development and validation of the general measure (1993) J. Clin. Oncol., 11, pp. 570-579
Hwang, S. S., Chang, V. T., Kasimis, B., Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) J. Pain Symptom Manage., 23, pp. 190-200
Mertens, W. C., Stitt, L., Porter, A. T., Strontium-89 therapy and relief of pain in patients with prostate carcinoma metastatic to bone: a dose response relationship? (1993) Am. J. Clin. Oncol., 16, pp. 238-242
Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group (1996) J. Clin. Oncol., 14, pp. 2552-2559
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
Purpose: We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. Methods: 25 patients (12 women; mean age 65 ± 13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70 ± 12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69 ± 12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). Results: Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P < 0.01) and group C (P < 0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. Conclusion: Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately. © 2005 Elsevier Inc. All rights reserved.
Purpose: We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. Methods: 25 patients (12 women; mean age 65 ± 13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70 ± 12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69 ± 12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). Results: Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P < 0.01) and group C (P < 0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. Conclusion: Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately. © 2005 Elsevier Inc. All rights reserved.
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
No results. |
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
Other filter: ([btitle,keywords] "Combined Therapy" OR ...
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (409 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (397 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (346 views) (PDF 10 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (288 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B
* Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans (396 views)
Leuk Lymphoma (ISSN: 1042-8194, 1026-8022linking), 2007 Sep; 48(9): 1721-1727.
Impact Factor: 1.512
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (416 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Paone G, Klain M, Salvatore B, Capacchione D, Soricelli A, Pace L, Salvatore M
* Hematological Toxicity in Patients with Painful Bone Metastases Treated with Sr-89 and Zoledronic Acid (210 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Storto G, Paone G, Ibello F, Klain M, Liuzzi R, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (293 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (360 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (409 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (397 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (346 views) (PDF 10 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (288 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B
* Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans (396 views)
Leuk Lymphoma (ISSN: 1042-8194, 1026-8022linking), 2007 Sep; 48(9): 1721-1727.
Impact Factor: 1.512
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (416 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Paone G, Klain M, Salvatore B, Capacchione D, Soricelli A, Pace L, Salvatore M
* Hematological Toxicity in Patients with Painful Bone Metastases Treated with Sr-89 and Zoledronic Acid (210 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Storto G, Paone G, Ibello F, Klain M, Liuzzi R, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (293 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (360 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
10 Records (7 excluding Abstracts).
Total impact factor: 29.434 (19.208 excluding Abstracts).
Total 5 year impact factor: 32.102 (20.188 excluding Abstracts).
Total impact factor: 29.434 (19.208 excluding Abstracts).
Total 5 year impact factor: 32.102 (20.188 excluding Abstracts).
394 views. Last view on Tuesday 02 May 2023, 15:57:26
ibb.cnr.it
